- Home
- FBIOP vs KPRX Comparison
FBIOP vs KPRX Comparison
Compare FBIOP & KPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FBIOP
- KPRX
- Stock Information
- Founded
- FBIOP N/A
- KPRX 1998
- Country
- FBIOP United States
- KPRX United States
- Employees
- FBIOP 101
- KPRX N/A
- Industry
- FBIOP Biotechnology: Pharmaceutical Preparations
- KPRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- FBIOP Health Care
- KPRX Health Care
- Exchange
- FBIOP Nasdaq
- KPRX Nasdaq
- Market Cap
- FBIOP N/A
- KPRX 8.3M
- IPO Year
- FBIOP N/A
- KPRX N/A
- Fundamental
- Price
- FBIOP $6.15
- KPRX $3.12
- Analyst Decision
- FBIOP
- KPRX Strong Buy
- Analyst Count
- FBIOP 0
- KPRX 1
- Target Price
- FBIOP N/A
- KPRX $10.00
- AVG Volume (30 Days)
- FBIOP N/A
- KPRX 11.2K
- Earning Date
- FBIOP N/A
- KPRX 05-20-2025
- Dividend Yield
- FBIOP N/A
- KPRX N/A
- EPS Growth
- FBIOP N/A
- KPRX N/A
- EPS
- FBIOP N/A
- KPRX 0.87
- Revenue
- FBIOP N/A
- KPRX $16,020,000.00
- Revenue This Year
- FBIOP N/A
- KPRX N/A
- Revenue Next Year
- FBIOP N/A
- KPRX N/A
- P/E Ratio
- FBIOP N/A
- KPRX $3.68
- Revenue Growth
- FBIOP N/A
- KPRX N/A
- 52 Week Low
- FBIOP N/A
- KPRX $2.51
- 52 Week High
- FBIOP N/A
- KPRX $5.55
- Technical
- Relative Strength Index (RSI)
- FBIOP 47.56
- KPRX 50.24
- Support Level
- FBIOP $6.36
- KPRX $3.18
- Resistance Level
- FBIOP $6.80
- KPRX $3.48
- Average True Range (ATR)
- FBIOP 0.37
- KPRX 0.19
- MACD
- FBIOP 0.01
- KPRX 0.02
- Stochastic Oscillator
- FBIOP 45.52
- KPRX 45.39
About FBIOP Fortress Biotech Inc.
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology and therapeutics sectors.
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.